---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076624"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-06-23T11:00:41+00:00"
generated_at: "2026-06-23T11:05:22.601882+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B

## Summary
- Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.
- NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.
- NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.
- Deal transforms Nuvectis into late-stage clinical company with two best-in-class potential assets.
- Agreement subject to financing conditions to ensure sufficient capital for product development.

## SEC filing metadata
- accession: 0001104659-26-076624
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-06-23T11:00:41+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/0001104659-26-076624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076624
- JSON: https://secwatch.observer/filing/0001104659-26-076624.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.